Kaitlin Hiddle
Psychiatric/Mental Health · Bentonville, ARNPI 1609305929
Payments from drug & device makers
Across 117 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$504
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
- Johnson & Johnson$207
- Vanda Pharmaceuticals Inc.$172
- Axsome Therapeutics, Inc.$167
- Teva Pharmaceuticals USA, Inc.$162
- plus $736 from 13 others
What the payments were for
- Food & beverage$2,12097%
- Education$773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $504 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $250 |
| Johnson & Johnson | 6 | $207 |
| Vanda Pharmaceuticals Inc. | 7 | $172 |
| Axsome Therapeutics, Inc. | 9 | $167 |
| Teva Pharmaceuticals USA, Inc. | 8 | $162 |
| Lundbeck LLC | 8 | $134 |
| Otsuka America Pharmaceutical, Inc. | 8 | $127 |
| Corium, LLC | 6 | $99 |
| Alkermes, Inc. | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Indivior Inc. | 3 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Eisai Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,197 in reported general payments places this provider in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $16,276 |
| Aripiprazole | 13 | $941 |
| Lurasidone Hcl | 14 | $549 |
| Trazodone Hcl | 22 | $545 |
| Doxepin Hcl | 14 | $478 |
| Gabapentin | 33 | $315 |
| Paroxetine Hcl | 13 | $142 |
| Clonazepam | 11 | $140 |
| Alprazolam | 19 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $127 | $16,27611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Bentonville
- Linda WestBentonville$3K
- Christie KellerFayetteville$167K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
- Mallori LevengoodPine Bluff$11K
- Jennifer PenneFayetteville$11K
- Stephanie ParishSearcy$9K
- Elizabeth HardyTexarkana$8K
- Tammy HawkinsJonesboro$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.